Navigation Links
Dynatronics Announces Fiscal Year 2008 Operating Results
Date:9/29/2008

that we are positioned to capitalize on the strategic plans we set in place last year," said Cullimore.

"Several factors are expected to help us become profitable," Cullimore continued. "Increased sales and improved margins will be key. The introduction of our first consolidated catalog in September 2008 is expected to give sales a strong boost going into the second quarter of the new fiscal year. In addition, a new pricing strategy is expected to improve margins. This includes the first price increase for our core products in over 20 years. The new catalog not only showcases more than 12,000 products, but facilitates a cohesive sales effort."

During fiscal year 2008, the company introduced the new Synergie Elite line of aesthetic products. "This is the first major redesign of Dynatronics' popular cellulite reduction and microdermabrasion devices, which should bring renewed interest to this high-margin product line," reported Kelvyn H. Cullimore Sr., vice chairman of Dynatronics.

With 36 direct sales representatives in 29 states, the company's presence of direct sales professionals continues to grow. "Over the coming year we will focus on bringing experienced distributors and dealers on board in areas where representation was lost through market consolidation," stated Larry K. Beardall, executive vice president of sales and marketing. "The focus of bringing on more dealers and sales representatives is expected to fuel additional growth in the next fiscal year."

During the process of assimilating its 2007-2008 acquisitions, the company consolidated eight distribution facilities into three distribution warehouses. This consolidation of facilities is expected to result in reductions in labor and overhead expenses in excess of $2.1 million annually.

Dynatronics has scheduled a conference call for investors on Monday, September 29, 2008, at 3:00 p.m. ET. Those wishing to participate should call 800-839-9416 and use passcode 9321818. '/>"/>

SOURCE Dynatronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Dynatronics to Release Fourth Quarter and Year-end Results Monday, September 29, 2008; Conference Call Set for 3:00 p.m. ET
2. Dynatronics Elects Mark A. Crockett to its Board of Directors
3. Dynatronics Receives NASDAQ Minimum Bid Price Deficiency Letter
4. Dynatronics Acquisitions Boost Sales 80 Percent in Third Quarter
5. Dynatronics to Release Third Quarter Results Wednesday, May 14, 2008; Conference Call Set for 2:30 p.m. ET
6. Dynatronics Reduces Annual Expenses by $1.9 Million
7. Dynatronics Introduces New DynaPro Spinal Health System and X5 Turbo
8. Dynatronics Introduces New Synergie Elite Aesthetic Line
9. Dynatronics Acquisitions Increase Sales 100 Percent in Second Quarter
10. Dynatronics to Release Second Quarter Results Thursday, February 14, 2008; Conference Call Set for 4:30 p.m. ET
11. Dynatronics Announces $250,000 Increase in Stock Buyback Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... (Chicago) A recently FDA-approved device has been shown ... as much as 50 percent. When coupled with an ... Rush, the device facilitated the complete elimination of seizures ... in the decade-long clinical trials. , That,s good news ... in the U.S. living with epilepsy whose seizures can,t ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... (fool) has a lip smacking meaning here. Like Ekta ... nomenclature of the restaurants// here attracts customers. ... (Big Fool)", "Sabse Bada Bewakoof" (The Biggest Fool) and ... ,"The word 'bewakoof' is the only reason for ...
... An Israeli scientist wants to turn camel milk, a healthier ... desert.,The practised method of milking normally yields// some 1.5 litres ... the yield of 20 litres produced by cows. Yagil, however, ... 15 litres per camel a day. ,Traditionally seen ...
... organize a nationwide peaceful demonstration against the reservation quota in ... proposal to hike reservation seats started on the 27th April. ... by after the assembly poll in five states was not ... 2 will be a ‘‘show of strength’’ and send the ...
... in Angola to contain the cholera outbreak there says that 20,000 ... is an acute intestinal infection, which is caused in most cases ... It’s showing even more in other provinces now also. This week ... day and in some days more than 30 deaths," said Richard ...
... journal Nature has found that Gene therapy, which is used ... cancer//. US researcher, citing an animal study say that the ... than previously thought. ,However, experts from Great Ormond ... say that gene therapy in low doses does not cause ...
... the capital of India medical students are striking against ... new step when the students said that they are ... ,They were persuading school and college students to ... to increase the Other Backward Classes (OBC) quota in ...
Cached Medicine News:Health News:Milking the ship of the desert for 'white gold' 2Health News:Nationwide Strike on May 2nd by Medicos on Reservation Issue 2Health News:'Bubble Boy' Gene Therapy Causes Cancer? 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... CVS Caremark Corporation (NYSE: CVS ), today announced ... ended September 30, 2011. (Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO) ... Net revenues increased 12.5% to a record $26.7 billion ... Retail Pharmacy segment revenues increased 3.8%, with same ...
... Bellicum Pharmaceuticals, Inc. today announced publication in ... results using a new therapy that demonstrated rapid and ... Inducible Apoptosis as a Safety Switch for Adoptive Cell ... ™ technology to eliminate donor T cells causing ...
Cached Medicine Technology:CVS Caremark Reports Third Quarter Results 2CVS Caremark Reports Third Quarter Results 3CVS Caremark Reports Third Quarter Results 4CVS Caremark Reports Third Quarter Results 5CVS Caremark Reports Third Quarter Results 6CVS Caremark Reports Third Quarter Results 7CVS Caremark Reports Third Quarter Results 8CVS Caremark Reports Third Quarter Results 9CVS Caremark Reports Third Quarter Results 10CVS Caremark Reports Third Quarter Results 11CVS Caremark Reports Third Quarter Results 12CVS Caremark Reports Third Quarter Results 13CVS Caremark Reports Third Quarter Results 14CVS Caremark Reports Third Quarter Results 15Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 2Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 3Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: